A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma(TAISHAN-301)

A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma(TAISHAN-301) is a phase 3 interventional study registered as NCT06629597, led by MediLink Therapeutics (Suzhou), and active but no longer recruiting on the registry. Official title: A Randomised, Controlled, Multicenter Phase III Clinical Study of YL201 Versus Investigator's Choice of Chemotherapy in Subjects With Recurrent or Metastatic Nasopharyngeal Carcinoma Who Have Failed Prior PD-(L)1 Inhibitor and at Least Two Lines of Chemotherapy. Planned enrolment is 400 participants (estimated). The study started in 2024-12-31 and primary completion is expected in 2027-12-01. No results have been posted on ClinicalTrials.gov.